{"version":"1.0","provider_name":"Basel Area Business &amp; Innovation","provider_url":"https:\/\/test.baselarea.swiss\/de\/","author_name":"martin","author_url":"https:\/\/test.baselarea.swiss\/de\/author\/martin\/","title":"VectivBio erl\u00f6st 125 Millionen Dollar aus Aktienverkauf","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"FOEJmWH2wA\"><a href=\"https:\/\/test.baselarea.swiss\/de\/blog-post\/vectivbio-erlost-125-millionen-dollar-aus-aktienverkauf\/\">VectivBio erl\u00f6st 125 Millionen Dollar aus Aktienverkauf<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/test.baselarea.swiss\/de\/blog-post\/vectivbio-erlost-125-millionen-dollar-aus-aktienverkauf\/embed\/#?secret=FOEJmWH2wA\" width=\"600\" height=\"338\" title=\"&#171;VectivBio erl\u00f6st 125 Millionen Dollar aus Aktienverkauf&#187; &#8212; Basel Area Business &amp; Innovation\" data-secret=\"FOEJmWH2wA\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/test.baselarea.swiss\/\/wp-content\/uploads\/2021\/04\/Biotech_Engimmune-news.jpg","thumbnail_width":800,"thumbnail_height":600,"description":"VectivBio hat den Abschluss des Zeichnungsangebots f\u00fcr 16'700'000 Stammaktien bekanntgegeben. Damit erzielte die Basler Biotechfirma einen Bruttoerl\u00f6s von rund 125 Millionen Dollar. Er soll in die Weiterentwicklung des Produktkandidaten f\u00fcr seltene, schwere Magen-Darm-Krankheiten fliessen."}